Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003162568> ?p ?o ?g. }
- W2003162568 endingPage "636" @default.
- W2003162568 startingPage "622" @default.
- W2003162568 abstract "To compare the effects of a daily oral 1-mg dose of continuous 17beta-estradiol (E2) plus intermittent (3 days off, 3 days on) norgestimate (NGM) 90 microg (n = 221), an oral 2-mg dose of continuous E2 plus intermittent NGM 180 microg (n = 219), and an oral 2-mg dose of continuous E2 plus continuous norethisterone acetate (NETA) 1 mg (n = 217) on blood lipids and lipoproteins in postmenopausal women.The present study was undertaken because some progestins have adverse effects on lipid profiles, thereby negating the favorable effects of estrogens.This was a multicenter, randomized, parallel-group trial that focused primarily on the 2 marketed regimens--E2 1 mg/NGM 90 microg and E2/NETA. Both subjects and investigators were blinded to the intermittent regimens; the continuous combined regimen was administered open-label. After a minimum 12-hour overnight fast, blood samples were collected at baseline and during months 7 and 12 to determine lipid and lipoprotein concentrations using validated methods.E2 1 mg/NGM 90 microg was associated with significant (ie, the 95% CI did not include 0) increases in high-density lipoprotein cholesterol (HDL-C) (6.8% [95% CI = 4.7%, 9.0%] and 4.8% [2.3%, 7.2%] at months 7 and 12, respectively) and high-density lipoprotein 2 cholesterol (HDL2-C) (10.8% [6.2%, 15.3%] and 24.1% [18.9%, 29.4%]) concentrations, and decreases in total cholesterol (-7.7% [-9.0%, -6.3%] and -9.2% [-10.5%, -7.9%]), low-density lipoprotein cholesterol (-14.3% [-16.3%, -12.4%] and -14.9% [-16.7%, -13.2%]), and lipoprotein(a) (-30.6% [-41.4%, -20.0%] at month 12) concentrations. A significant difference (P < 0.001 by analysis of variance) between the E2 1-mg/NGM 90-microg and NETA regimens was seen for HDL-C and HDL2-C concentrations, which were elevated in subjects receiving E2 1 mg/NGM 90 microg but reduced (-9.1% [-11.1%, -7.1%] and -12.3% [-14.3%, -10.3%] for HDL-C at months 7 and 12, respectively; -14.2% [-18.0%, -10.4%] and -2.5% [-7.8%, +2.8%] for HDL2-C at months 7 and 12, respectively) in those receiving E2/NETA.In the present study, continuous E2 1 mg/NGM 90 microg was associated with beneficial effects on lipids and lipoproteins in healthy postmenopausal women, effects that were greater at least for HDL-C and HDL2-C than those observed with continuous combined E2/NETA. The applicability of the study results to women with preexisting cardiovascular disease or dyslipidemia, or those who are overweight, remains to be investigated." @default.
- W2003162568 created "2016-06-24" @default.
- W2003162568 creator A5009892971 @default.
- W2003162568 creator A5026965965 @default.
- W2003162568 creator A5053168114 @default.
- W2003162568 date "2000-05-01" @default.
- W2003162568 modified "2023-10-05" @default.
- W2003162568 title "Effects on serum lipid profiles of continuous 17β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/ norethisterone acetate hormone replacement therapy" @default.
- W2003162568 cites W1946263363 @default.
- W2003162568 cites W1976991737 @default.
- W2003162568 cites W1982391258 @default.
- W2003162568 cites W1983756928 @default.
- W2003162568 cites W1992815912 @default.
- W2003162568 cites W2008491340 @default.
- W2003162568 cites W2012090732 @default.
- W2003162568 cites W2016311358 @default.
- W2003162568 cites W2025739640 @default.
- W2003162568 cites W2026264139 @default.
- W2003162568 cites W2031141001 @default.
- W2003162568 cites W2032888963 @default.
- W2003162568 cites W2036021424 @default.
- W2003162568 cites W2038738097 @default.
- W2003162568 cites W2046800613 @default.
- W2003162568 cites W2050108803 @default.
- W2003162568 cites W2069877304 @default.
- W2003162568 cites W2071268137 @default.
- W2003162568 cites W2072537818 @default.
- W2003162568 cites W2076386730 @default.
- W2003162568 cites W2077760013 @default.
- W2003162568 cites W2083352049 @default.
- W2003162568 cites W2083754669 @default.
- W2003162568 cites W2088705123 @default.
- W2003162568 cites W2093444286 @default.
- W2003162568 cites W2106949582 @default.
- W2003162568 cites W2113264115 @default.
- W2003162568 cites W2116404316 @default.
- W2003162568 cites W2122772014 @default.
- W2003162568 cites W2145912168 @default.
- W2003162568 cites W2317012058 @default.
- W2003162568 cites W2429567452 @default.
- W2003162568 cites W2615633554 @default.
- W2003162568 cites W4237321678 @default.
- W2003162568 cites W4242752862 @default.
- W2003162568 cites W4246052774 @default.
- W2003162568 cites W4249825849 @default.
- W2003162568 doi "https://doi.org/10.1016/s0149-2918(00)80049-1" @default.
- W2003162568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10868559" @default.
- W2003162568 hasPublicationYear "2000" @default.
- W2003162568 type Work @default.
- W2003162568 sameAs 2003162568 @default.
- W2003162568 citedByCount "33" @default.
- W2003162568 countsByYear W20031625682012 @default.
- W2003162568 countsByYear W20031625682015 @default.
- W2003162568 countsByYear W20031625682019 @default.
- W2003162568 countsByYear W20031625682022 @default.
- W2003162568 crossrefType "journal-article" @default.
- W2003162568 hasAuthorship W2003162568A5009892971 @default.
- W2003162568 hasAuthorship W2003162568A5026965965 @default.
- W2003162568 hasAuthorship W2003162568A5053168114 @default.
- W2003162568 hasConcept C126322002 @default.
- W2003162568 hasConcept C134018914 @default.
- W2003162568 hasConcept C139572402 @default.
- W2003162568 hasConcept C2777164284 @default.
- W2003162568 hasConcept C2777956591 @default.
- W2003162568 hasConcept C2778163477 @default.
- W2003162568 hasConcept C2779279991 @default.
- W2003162568 hasConcept C2780072125 @default.
- W2003162568 hasConcept C2780159708 @default.
- W2003162568 hasConcept C2780541478 @default.
- W2003162568 hasConcept C2780835420 @default.
- W2003162568 hasConcept C2781039349 @default.
- W2003162568 hasConcept C2781413609 @default.
- W2003162568 hasConcept C2908647359 @default.
- W2003162568 hasConcept C2986817661 @default.
- W2003162568 hasConcept C71924100 @default.
- W2003162568 hasConcept C99454951 @default.
- W2003162568 hasConceptScore W2003162568C126322002 @default.
- W2003162568 hasConceptScore W2003162568C134018914 @default.
- W2003162568 hasConceptScore W2003162568C139572402 @default.
- W2003162568 hasConceptScore W2003162568C2777164284 @default.
- W2003162568 hasConceptScore W2003162568C2777956591 @default.
- W2003162568 hasConceptScore W2003162568C2778163477 @default.
- W2003162568 hasConceptScore W2003162568C2779279991 @default.
- W2003162568 hasConceptScore W2003162568C2780072125 @default.
- W2003162568 hasConceptScore W2003162568C2780159708 @default.
- W2003162568 hasConceptScore W2003162568C2780541478 @default.
- W2003162568 hasConceptScore W2003162568C2780835420 @default.
- W2003162568 hasConceptScore W2003162568C2781039349 @default.
- W2003162568 hasConceptScore W2003162568C2781413609 @default.
- W2003162568 hasConceptScore W2003162568C2908647359 @default.
- W2003162568 hasConceptScore W2003162568C2986817661 @default.
- W2003162568 hasConceptScore W2003162568C71924100 @default.
- W2003162568 hasConceptScore W2003162568C99454951 @default.
- W2003162568 hasIssue "5" @default.
- W2003162568 hasLocation W20031625681 @default.
- W2003162568 hasLocation W20031625682 @default.
- W2003162568 hasOpenAccess W2003162568 @default.
- W2003162568 hasPrimaryLocation W20031625681 @default.